60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Stock Forecast & Price Target
60 Degrees Pharmaceuticals, Inc. Common Stock · NASDAQ
$1.08+0.00 (+0.00%)
15-min delayed · Aug 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering 60 Degrees Pharmaceuticals, Inc. Common Stock, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.70 to $24.00 (about 6.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $13.85 sits 1182% above the current $1.08. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.89 next quarter toward $-3.58 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to 60 Degrees Pharmaceuticals, Inc. Common Stock.
As of Aug, 1 of 2 firms rate SXTP a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SXTP EPS & revenue forecast
EPS · NEXT QUARTER
$-0.89
Range $-0.89 – $-0.89 · 1 analysts · -89% YoY
Next period, 1 analysts expect 60 Degrees Pharmaceuticals, Inc. Common Stock to earn $-0.89 a share (range $-0.89 – $-0.89), versus $-8.17 a year earlier. Full-year consensus is $-3.45, growing to $-3.58 the year after.
REVENUE · NEXT QUARTER
$310.0K
Range $310.0K – $310.0K · 1 analysts · +2% YoY
Revenue is expected to reach $310.0K (range $310.0K – $310.0K), +2.2% year-over-year. Full-year consensus is $1.0M, rising to $1.7M next year.
Top analysts covering 60 Degrees Pharmaceuticals, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SXTP.
#1
EW
Edward White
HC Wainwright & Co. · Rank #283
Hold
No targeton SXTP
Overall win rate
31%
+ Follow
#2
LW
Lucas Ward
Ascendiant Capital
Buy
$3.70+242.6% to target
Coverage
—
+ Follow
#3
MK
Matthew Keller
HC Wainwright & Co.
Hold
No targeton SXTP
Coverage
—
+ Follow
SXTP stock forecast FAQ
What is SXTP's average 12-month price target?+
The 1 analysts with a live target average $13.85 for 60 Degrees Pharmaceuticals, Inc. Common Stock over the next 12 months, ranging from a $24.00 high to a $3.70 low.
Is SXTP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SXTP?+
The Street-high target is $24.00, and the Street-low is $3.70 (Ascendiant Capital). The average of all 1 active targets is $13.85.
How many Wall Street analysts cover SXTP?+
2 analysts have an active rating on 60 Degrees Pharmaceuticals, Inc. Common Stock, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering SXTP?+
Among analysts who currently cover SXTP, Edward White of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #283). Their current call is Hold.
What is 60 Degrees Pharmaceuticals, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.89 per share (range $-0.89 – $-0.89) across 1 analysts. Full-year EPS is projected at $-3.45, rising to $-3.58 the following year.
How much revenue is 60 Degrees Pharmaceuticals, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $310.0K (range $310.0K – $310.0K). Full-year revenue is projected at $1.0M, growing to $1.7M next year.
Have analysts been upgrading or downgrading SXTP lately?+
As of Aug, 1 of 2 firms rate SXTP a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SXTP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
